Condition
Estrogen Receptor-Positive
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
50.0%
1 terminated out of 2 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Terminated1
Unknown1
Clinical Trials (2)
Showing 2 of 2 trials
NCT04669587Phase 1UnknownPrimary
ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)
NCT03566485Phase 1Terminated
Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
Showing all 2 trials